UNCY
Unicycive Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.52
+4.61%Sep 29, 2026, 11:51 UTC
Unicycive Therapeutics, Inc. appointed Meredith S. Manning as an independent director on its board of directors, effective October 1, 2026.
Sep 29, 2026, 11:05 UTC
Unicycive Therapeutics resubmitted its New Drug Application to the FDA for oxylanthanum carbonate, an investigational oral phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis.
Source:Sep 25, 2026, 18:57 UTC
A class action was filed on behalf of investors who purchased Unicycive Therapeutics, Inc. securities between December 29, 2025 and June 29, 2026, as announced by shareholder rights law firm Robbins LLP.
Sep 11, 2026, 18:31 UTC
Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. on behalf of investors who acquired Unicycive securities between December 29, 2025 and June 29, 2026.
Sep 11, 2026, 00:00 UTC
A securities class action lawsuit was filed against Unicycive Therapeutics on behalf of investors who purchased securities between December 29, 2025 and June 29, 2026, alleging false and misleading statements about its third-party manufacturing vendor's compliance with good manufacturing practices.
Source:Sep 7, 2026, 11:30 UTC
Unicycive Therapeutics, Inc. has been sued for securities law violations, and the DJS Law Group is inviting affected investors to discuss their rights.
Source:Aug 12, 2026, 00:00 UTC
Unicycive Therapeutics reported its Q2 2026 financial results, with a net loss of $1.7 million and diluted EPS of -$0.06, compared to a net loss of $6.5 million in Q2 2025.
Jun 30, 2026, 16:51 UTC
The FDA issued a second Complete Response Letter to Unicycive Therapeutics regarding the resubmitted OLC NDA, citing the same third-party manufacturing deficiencies as in the prior CRL.